Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma

詳細情報 詳細情報について

• CRID

  1361137045591612800

• DOI

  10.1007/s00384-017-2800-1

• ISSN

  14321262

  01791958

• Web Site

  http://link.springer.com/article/10.1007/s00384-017-2800-1/fulltext.html

  http://link.springer.com/content/pdf/10.1007/s00384-017-2800-1.pdf

• データソース種別

  • Crossref